Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5798-5805

  Challita Eid, Pia M ^a   Morrison, Kendall ^a   Etessami, Soudabeh ^a   An, Zili ^a   Morrison, Karen J ^a   Perez Villar, Juan J ^a   Raitano, Arthur B ^a   Jia, Xiao Chi ^a   Gudas, Jean M ^a   Kanner, Steven B ^a   Jakobovits, Aya ^a  

^a Agensys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 120.545; MONOCLONAL ANTIBODY 92.30; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CELL COMMUNICATION; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SYNTHESIS; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; LUNG CARCINOMA; LYMPH NODE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BONE NEOPLASMS; CELL COMMUNICATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; NEOPLASM TRANSPLANTATION; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250847132     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3849     Document Type: Article

References (26)

1. Weiner LM, Carter P. Tunable antibodies. Nat Biotechnol 2005;23:556-7.
2. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1991;96:14523-8.
3. Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005;65:6435-42.
4. Rodeberg DA, Nuss RA, Elsawa SF, et al. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005;11:4545-52.
5. Alves PM, Faure O, Graff-Dubois S, et al. STEAP, a prostate tumor antigen, is a target of human CD8(+) T cells. Cancer Immunol Immunother 2006;55:1515-23.
6. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
7. Muller AJ, Young JC, Pendergast AM, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 1991;11:1785-92.
8. Ko K, Arora P, Lee W, et al. Biochemical and functional characterization of intercellular adhesion and gap junctions in fibroblasts. Am J Physiol Cell Physiol 2000;279:C147-57.
9. Goldberg GS, Bechberger JF, Naus CC. A pre-loading method of evaluating gap junctional communication by fluorescent dye transfer. Biotechniques 1995;8:490-7.
10. Govindarajan R, Zhao S, Song XH, et al. Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by α-catenin. J Biol Chem 2002;277:50087-97.
11. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001;98:2658-63.
12. Jorgensen NR, Teilmann SC, Henriksen Z, et al. Activation of L-type calcium channels is required for gap junction-mediated intercellular calcium signaling in osteoblastic cells. J Biol Chem 2003;278:4082-6.
13. Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006;66:4795-801.
14. Naus CC. Gap junctions and tumour progression. Can J Physiol Pharmacol 2002;80:136-41.
15. Zhang W, DeMattia JA, Song H, et al. Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J Neurosurg 2003;98:846-53.
16. Zhang W, Nwagwu C, Le DM, et al. Increased invasive capacity of connexin 43-overexpressing malignant glioma cells. J Neurosurg 2003;99:1039-46.
17. Tate AW, Lung T, Radhakrishnan A, et al. Changes in gap junctional connexin isoforms during prostate cancer progression. Prostate 2006;66:19-31.
18. Sanchez-Pulido L, Rojas AM, Valencia A, et al. ACRATA: a novel electron transfer domain associated to apoptosis and cancer. BMC Cancer 2004;4:98-103.
19. Ohgami RS, Campagna DR, Greer EL, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 2005;37:1264-9.
20. Yamada T, Hiraoka Y, Das Gupta TK, et al. Regulation of mammalian cell growth and death by bacterial redox proteins: relevance to ecology and cancer therapy. Cell Cycle 2004;3:752-5.
21. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-40.
22. Gu Z, Yamashiro J, Kono E, et al. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005;65:9495-500.
23. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
24. Ross JS, Gray KE, Webb IJ, et al. Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev 2005;24:521-37.
25. Afar DE, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 2004;3:921-32.
26. Zhao XY, Schneider D, Biroc SL, et al. Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res 2005;65:2846-53.